Trial Profile
A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Loncastuximab tesirine (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms LOTIS 4
- Sponsors ADC Therapeutics
- 10 Nov 2020 According to clinicaltrials.gov the study was stopped in a limited number of patients, no additional activity was evident for the combination vs. Loncastuximab tesirine monotherapy.
- 10 Nov 2020 Status changed from active, no longer recruiting to discontinued.
- 24 Jan 2020 Planned End Date changed from 27 Aug 2022 to 29 Jan 2021.